DNF/Fluorouracil

This tender pertains to the procurement of Fluorouracil, identified by the abbreviation DNF/Fluorouracil. Fluorouracil (5-FU) is a widely used chemotherapy medication, an antimetabolite that interferes with the synthesis of DNA and RNA, thereby inhibiting the growth of cancer cells. This tender is likely issued by a healthcare institution or a government health agency to secure a supply of this essential pharmaceutical for cancer treatment. The scope of procurement may include various formulations and dosages of Fluorouracil, depending on the specific needs outlined in the tender documents. Bidders are expected to be pharmaceutical manufacturers or authorized distributors with the capability to supply high-quality, registered medicinal products. Compliance with pharmaceutical quality standards, regulatory approvals, and secure supply chain management are critical requirements. The tender aims to ensure the availability of Fluorouracil for patients undergoing chemotherapy, supporting oncology services and patient care within the procuring entity's jurisdiction. The successful award will guarantee a consistent and reliable source of this vital chemotherapeutic agent.

This is a services contract in the health and medical services, trade and industry and general supplies sectors. Located in Chile, Latin America, this opportunity is open to firms and consortiums.

Published through Chile Mercado Publico, a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for services in the health and medical services sector. Service contracts are typically evaluated on both technical quality and price, and may require bidders to demonstrate relevant experience and qualified personnel. This contract has already been awarded. The information is published for transparency and market intelligence purposes.